BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

Conditions: Malignant Melanoma

First Posted Date: 2014-07-10

Last Posted Date: 2017-02-08

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02186249

Locations: 🇺🇸
Medstar Health Research Institute, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 61 locations

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Phase 2

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Nivolumab
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine

First Posted Date: 2014-07-04

Last Posted Date: 2023-11-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 294

Registration Number: NCT02181738

Locations: 🇺🇸
Local Institution - 0025, Boston, Massachusetts, United States
🇮🇹
Local Institution - 0019, Bologna, Italy
🇬🇧
Local Institution - 0026, Oxford, Oxfordshire, United Kingdom

and more 35 locations

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: DCV/ASV/BMS-791325
Drug: Sofosbuvir
Drug: Ribavirin
Drug: Peginterferon α-2a

First Posted Date: 2014-06-26

Last Posted Date: 2020-08-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT02175966

Locations: 🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
Indiana University Health - University Hospital, Indianapolis, Indiana, United States
🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States

and more 4 locations

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

Phase 1

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Sertraline
Drug: Escitalopram
Drug: DCV 3DAA FDC
Drug: BMS-791325

First Posted Date: 2014-06-26

Last Posted Date: 2015-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 41

Registration Number: NCT02175602

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: DCV/ASV/BMS-791325

First Posted Date: 2014-06-23

Last Posted Date: 2020-10-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 199

Registration Number: NCT02170727

Locations: 🇨🇳
Local Institution, Taoyuan, Taiwan

Post-marketing Study Assessing the Long-Term Safety of Abatacept

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2014-06-23

Last Posted Date: 2017-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100000

Registration Number: NCT02169544

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Phase 1

Completed

Conditions: HIV/AIDS

Interventions: Drug: Moxifloxacin
Drug: Placebo
Drug: Efavirenz

First Posted Date: 2014-06-17

Last Posted Date: 2015-09-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT02164812

Locations: 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Conditions: Chronic Hepatitis C

First Posted Date: 2014-06-12

Last Posted Date: 2016-01-29

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02161939

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸
Piedmont Transplant, Atlanta, Georgia, United States

and more 17 locations

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-06-09

Last Posted Date: 2019-07-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT02159365

Locations: 🇺🇸
Baptist Health Medical Group Oncology, Miami, Florida, United States
🇺🇸
Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
🇺🇸
Comprehensive Blood And Cancer Center, Bakersfield, California, United States

and more 26 locations

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Darunavir
Drug: Lopinavir/Ritonavir
Drug: Ritonavir

First Posted Date: 2014-06-09

Last Posted Date: 2015-11-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT02159352

Locations: 🇺🇸
Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy